| Name | Sofalcone |
|---|---|
| Synonyms |
{5-[(3-methyl-2-butenyl)oxy]-2-{p-[(3-methyl-2-butenyl)oxy]cinnamoyl}phenoxy}acetic acid
2’-cboxymethoxy-4,4’-bis(3-methyl-2-butenyloxy)chalcone Sofalcone //BP (E)-Sofalcone 2-(5-((3-Methylbut-2-en-1-yl)oxy)-2-(3-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)acryloyl)phenoxy)acetic acid su88 SOFALCONE(2'-ETHOXYCBONYLMETHOXY-4'-(3-METHYL-2-BUTENYL-OXY)ACETOPHENONE) 2-[5-[(3-Methyl-2-buten-1-yl)oxy]-2-[3-[4-[(3-Methyl-2-buten-1-yl)oxy]phenyl]-1-oxo-2-propen-1-yl]phenoxy]acetic Acid Mr. Method ketone MFCD00868207 SOFALCONE JP isoprenylchalcone SOFALCONE MICROPOWDER aceticacid,(5((3-methyl-2-butenyl)oxy)-2-(3-(4-((3-methyl-2-butenyl)oxy)pheny SOFALCONE ({5-[(3-methylbut-2-en-1-yl)oxy]-2-[(2E)-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl]phenyl}oxy)acetic acid Acetic acid, 2-[5-[(3-methyl-2-buten-1-yl)oxy]-2-[3-[4-[(3-methyl-2-buten-1-yl)oxy]phenyl]-1-oxo-2-propen-1-yl]phenoxy] solon {5-[(3-Methyl-2-buten-1-yl)oxy]-2-[(2E)-3-{4-[(3-methyl-2-buten-1-yl)oxy]phenyl}-2-propenoyl]phenoxy}acetic acid [5-[(3-Methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]acetic acid {5-[(3-Methylbut-2-en-1-yl)oxy]-2-[(2E)-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl]phenoxy}acetic acid [4,4'-Bis(3-methyl-2-butenyloxy)chalcon-2'-yloxy]acetic acid Sofacone l)-1-oxo-2-propenyl)phenoxy) 2-[5-(3-methylbut-2-enoxy)-2-[(E)-3-[4-(3-methylbut-2-enoxy)phenyl]-1-oxoprop-2-enyl]phenoxy]acetic acid [5-[(3-Methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]acetic Acid |
| Description | Sofalcone, a gastric antiulcer agent in clinical use, is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium. |
|---|---|
| Related Catalog | |
| Target |
Heme oxygenase-1[1] |
| In Vitro | Sofalcone (50 μmol/L) significantly increases HO-1 mRNA expression compare with the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis demonstrates that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs[1]. |
| Cell Assay | Primary HUVECs are seeded at 60 000 cells per well and incubated at 37°C for 14 to 16 hours to allow tube formation. Cells are then cultured in the presence of either TNF-α (10 ng/mL) alone, with both TNF-α (10 ng/mL) and Sofalcone 50 μM, or control media for 8 to 12 hours. Tube formation is assessed, and images are captured using microscope at ×4 magnification[1]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 650.0±55.0 °C at 760 mmHg |
| Molecular Formula | C27H30O6 |
| Molecular Weight | 450.523 |
| Flash Point | 215.2±25.0 °C |
| Exact Mass | 450.204254 |
| PSA | 82.06000 |
| LogP | 6.70 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.579 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
~%
64506-49-6 |
| Literature: US4085135 A1, ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |